title: The effect of agonists and antagonists of platelet aggregation on von Willebrand factor-mediated platelet agglutination.
abstract: Ristocetin-induced platelet agglutination (RIPA) in EDTA-treated citrated platelet-rich plasma was reduced to 49 +/- 11% by 1.25 microM ADP, 41 +/- 14% by 1 microM A23187, and 26 +/- 7% by 0.1 microgram/ml platelet activating factor (PAF). The effect of 5-110 microM epinephrine was not dose-dependent, but varied between donors, with RIPA from 56-100% of the control. The inhibitory effects of these agonists were not altered by prior treatment of platelets with aspirin. Prior addition of 200 microM ATP (an ADP receptor antagonist acting at both high and low affinity ADP receptors) prevented the inhibitory action of ADP but not that of A23187 or PAF, suggesting that the inhibitory actions of the latter are not mediated by released ADP. As 700 microM 8-bromoadenosine 5-diphosphate (an ADP receptor antagonist acting mainly at the high affinity receptor) did not prevent ADP-induced inhibition of RIPA, interaction of ADP with the low affinity receptor is presumably responsible for its inhibitory action. As A23187, but not phorbol myristate acetate (0.1 microM) inhibited RIPA, an increase in intracellular calcium ions rather than direct stimulation of protein kinase C appears to mediate agonist-induced inhibition. Cytochalasin B (10.5-21 microM), dibucaine (0.5-1 mM), and prostaglandin E1 (25 nM), added before or after the agonist, prevented or reversed ADP-, A23187-, and PAF-induced inhibition of RIPA, suggesting that the state of the platelet cytoskeleton affects inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Faculty of Medicine, University of Newcastle, N.S.W., Australia.
authors.forename: J
authors.initials: J
authors.lastname: McPherson
authors.forename: M B
authors.initials: MB
authors.lastname: Zucker
authors.forename: E A
authors.initials: EA
authors.lastname: Mauss
authors.forename: S
authors.initials: S
authors.lastname: Brownlea
mesh_terms: D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D012310:Ristocetin / Q000037:antagonists & inhibitors; D014841:von Willebrand Factor / Q000502:physiology*
chemical_list: D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor; D012310:Ristocetin